Renalytix closes second tranche of private placement, raises ~$7M gross

Renalytix plc

Second Tranche of 26,815,841 ordinary shares at £0.20 each closed on April 24, 2024, following shareholder approval.
Gross proceeds from Second Tranche ~$7M; net proceeds expected to extend cash runway into calendar Q4 2024.
Post-issuance total ordinary shares outstanding: 154,368,191.
Company to file resale registration statement with SEC within 45 days of Second Closing.
First Tranche of 19,986,031 shares closed March 14, 2024; combined offering proceeds extend runway.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Renalytix plc entered into Placing Agreement with Stifel Nicolaus Europe Limited valued at up to an aggregate of 46,801,872 ordinary shares (effective 2024-03-12).

Action: entry
Agreement: equity purchase
Counterparty: Stifel Nicolaus Europe Limited
Value: up to an aggregate of 46,801,872 ordinary shares
Effective: 2024-03-12

Exact text from the filing

on March 12, 2024, Renalytix plc (the “ Company ”) entered into a Placing Agreement (the “ Placing Agreement ”) with Stifel Nicolaus Europe Limited

View on SEC.gov

284 material agreements filed in the last 30 days. Browse all material agreements →

Renalytix plc filing history →

Source: SEC EDGAR

accession 0000950170-24-048658

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.